ArticlePCN reports : psychiatry and clinical neurosciences2025
Acute exacerbation of major depressive disorder following valbenazine treatment for tardive dyskinesia: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute exacerbation of major depressive disorder following valbenazine treatment for tardive dyskinesia: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tardive dyskinesia (TD) is a movement disorder associated with long-term use of dopamine receptor-blocking agents. Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, effectively reduces TD symptoms, but it may also trigger or worsen depressive symptoms by reducing central dopamine and serotonin availability. Case Presentation: We report the case of a 52-year-old woman with major depressive disorder (MDD) and oral dyskinesia who experienced an acute mood deterioration after she began taking valbenazine 40 mg/day. She developed TD while receiving antipsychotic treatment for depression. After she achieved partial psychiatric improvement on lurasidone, we started valbenazine to address her dyskinesia. Within hours of the first dose, she reported markedly worse depressive symptoms, heightened anxiety, and significant functional decline, even though her dyskinesia improved. Her Hamilton Depression Rating Scale score increased from 30 before valbenazine to 40 the next day. We stopped valbenazine, and over the following month, she gradually regained mood stability. Conclusion: This case shows that valbenazine can acutely worsen preexisting depression. Clinicians should actively evaluate psychiatric history, assess current mood stability before prescribing, and monitor patients closely to identify and address mood changes promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.